T

he foundational patents on the CRISPR-Cas9 technology remain hung up in an ugly legal fight. But applications for new patents on specific uses of the genome-editing system continue to be filed.

The latest, published on Thursday but first filed in 2013, covers the use of CRISPR-Cas (it’s broader than just Cas9) in what are called nucleotide repeat disorders — basically, inherited diseases in which DNA stutters: A gene includes hundreds, instead of just a few, repeats of strings of letters such as CAG or CGG.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.